Stonepine Capital Management LLC Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Stonepine Capital Management LLC acquired a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 331,900 shares of the biotechnology company's stock, valued at approximately $1,908,000. Enanta Pharmaceuticals accounts for approximately 1.5% of Stonepine Capital Management LLC's investment portfolio, making the stock its 20th biggest holding. Stonepine Capital Management LLC owned about 1.56% of Enanta Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals in the fourth quarter worth about $26,000. Tower Research Capital LLC TRC lifted its holdings in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 2,274 shares during the period. Intech Investment Management LLC acquired a new stake in Enanta Pharmaceuticals in the fourth quarter worth about $58,000. Wells Fargo & Company MN lifted its holdings in Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after purchasing an additional 6,518 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Enanta Pharmaceuticals in the fourth quarter worth about $105,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ENTA shares. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.25.

Enanta Pharmaceuticals Trading Down 4.6%

NASDAQ:ENTA traded down $0.28 on Wednesday, hitting $5.79. 156,188 shares of the company's stock traded hands, compared to its average volume of 285,483. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.09 and a 1 year high of $17.24. The firm has a 50-day moving average price of $5.45 and a 200-day moving average price of $6.55. The company has a market cap of $123.77 million, a PE ratio of -1.17 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.